Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab

Daher, M., Lacouture, M. E., Rathkopf, D., Maki, R. G., Keohan, M. L., Gansukh, B., Chen, H., Abou-Alfa, G. K. (July 2011) Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. J Clin Oncol, 29 (21). e638-40. ISSN 1527-7755 (Electronic)0732-183X (Linking)

DOI: 10.1200/JCO.2010.34.5116


The insulin-like growth factor-1 receptor (IGFR1) is frequently overexpressed in a broad range of tumors. Its signaling has been shown to be involved in tumorigenesis and metastatic potential of multiple cancers.1 Drugs targeting this pathway began to be developed in the late 1990s, including monoclonal antibodies to IGFR1.2 Cixutumumab (IMC-A12; ImClone Systems, Bridgewater, NJ), a fully humanized monoclonal IgG1 antibody, binds to IGFR1 with high affinity, inhibiting its activation.3 Because IGFR1-targeted therapy is relatively new, the potential toxicities are not fully understood. IGF-1 has many physiologic roles that could potentially be compromised by the inhibition of its receptor. One of these roles is to enhance epidermal proliferative potential as well as keratinocyte cell migration.4 Therefore, potential dermatologic adverse effects can be anticipated when IGFR1 function is inhibited. An in-depth review of the literature did not reveal any previous reports that have addressed this issue. In this article, we describe four patients who were enrolled onto clinical trials using cixutumumab and subsequently developed skin and nail abnormalities.

Item Type: Paper
Uncontrolled Keywords: Aged Antibodies, Monoclonal/*adverse effects Antineoplastic Agents/*adverse effects Exanthema/chemically induced Female Humans Male Middle Aged Nail Diseases/*chemically induced/pathology Pruritus/chemically induced Receptor, IGF Type 1/*antagonists & inhibitors/immunology Skin Diseases/*chemically induced/pathology Thumb
Subjects: diseases & disorders > cancer
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > IGF
diseases & disorders > skin and connective diseases
diseases & disorders > cancer > drugs and therapies
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: 20 July 2011
Date Deposited: 21 Oct 2016 19:29
Last Modified: 21 Oct 2016 19:29
PMCID: PMC3138721
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving